Nature Neuroscience Publishes Data Demonstrating Potential Therapeutic Benefits of Karyopharm's SINE(TM) Compounds in the Treatment of Multiple Sclerosis
February 23, 2015 11:00 ET
|
Karyopharm Therapeutics
Research Conducted in Collaboration with Mount Sinai with Funding from the National Multiple Sclerosis Society and from the National Institute for Neurological Disorders and Stroke
Results...
Karyopharm to Present at Leerink Partners Global Healthcare Conference
February 05, 2015 08:30 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Michael G. Kauffman, MD, PhD, Chief Executive...
Karyopharm Announces Orphan Designation Granted by FDA for Selinexor (KPT-330) in Multiple Myeloma
January 08, 2015 08:30 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that its lead drug candidate, selinexor (KPT-330),...
Karyopharm to Present at J.P. Morgan 33rd Annual Healthcare Conference
January 07, 2015 16:01 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Michael G. Kauffman, MD, PhD, Chief Executive...
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
January 06, 2015 23:55 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a...
Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock
January 05, 2015 16:44 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common...
Karyopharm Announces Addition to the NASDAQ Biotechnology Index
December 15, 2014 08:56 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced today that it has been selected for addition to...
Karyopharm Initiates Third Registration-Directed Clinical Trial of Oral Selinexor (KPT-330)
December 11, 2014 08:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Dec. 11, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the initiation of the SADAL study, (Selinexor and...
Karyopharm Presents Positive Clinical Data for Selinexor (KPT-330) in NHL Patients at ASH 2014 Annual Meeting
December 08, 2014 13:30 ET
|
Karyopharm Therapeutics
NEWTON, Mass., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical data for its...
Karyopharm Presents Positive Combination Data for Selinexor (KPT-330) in Multiple Myeloma Patients at ASH 2014 Annual Meeting
December 08, 2014 13:00 ET
|
Karyopharm Therapeutics
- Selinexor Demonstrates Synergy in Combination with Approved Therapies for Multiple Myeloma -
- Durable Responses with Selinexor in Combination with Low-dose Dexamethasone in Heavily Pretreated...